Literature DB >> 10671909

Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

D S Ou-Yang1, S L Huang, W Wang, H G Xie, Z H Xu, Y Shu, H H Zhou.   

Abstract

AIMS: To investigate the distribution characteristics of CYP1A2 in a Chinese population, and to examine gender-related differences in CYP1A2 activity.
METHODS: Two hundred and twenty-nine healthy subjects, 120 men and 109 women, were enrolled in this study. CYP1A2 activity was measured by plasma paraxanthine/caffeine (1,7X/1,3,7X) ratio 6 h after administration of 300 mg caffeine. The concentrations of paraxanthine and caffeine in plasma were detected by h.p.l.c.
RESULTS: A 16-fold variation of CYP1A2 activity (range 0. 09 to 1.46) was shown in this study. The coefficient of variation (CV %) of CYP1A2 activity was 62.9%. Non-normal distribution of CYP1A2 activity was indicated by the Shapiro-Wilk test (P<0.001). Probit plots of CYP1A2 activity revealed a bimodal distribution with breakpoint of 1,7X/1,3,7X ratio of 0.12. The percentage of poor metabolizers (PMs) was 5.24% (95% CI: 2.35% approximately 8.13%) in this Chinese population. Residual analysis of the data also supported bimodality (P<0.01). The CYP1A2 activity of men was higher than that of women (median: 0.33 vs 0.23, P<0.001). A probit plot of CYP1A2 activity in men was shifted to the left compared with that in women. Based on phenotype, the gender-related difference was observed in extensive metabolizers (EMs) (P<0.001), but not in PMs (P >0.1). In addition, there was no sex-related difference in the incidence of PMs (P >0.1).
CONCLUSIONS: There is a phenotypic polymorphism in CYP1A2 activity in this Chinese population, and CYP1A2 activity is higher in men than that in women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10671909      PMCID: PMC2014904          DOI: 10.1046/j.1365-2125.2000.00128.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  49 in total

1.  Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.

Authors:  C P Denaro; M Wilson; P Jacob; N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  1996-03       Impact factor: 6.875

2.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

Authors:  K W Bock; D Schrenk; A Forster; E U Griese; K Mörike; D Brockmeier; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1994-08

3.  Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination.

Authors:  A Balogh; G Klinger; L Henschel; A Börner; R Vollanth; W Kuhnz
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  A population and family study of CYP1A2 using caffeine urinary metabolites.

Authors:  A Catteau; Y C Bechtel; N Poisson; P R Bechtel; C Bonaïti-Pellie
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods.

Authors:  E S Vesell; D W Gaylor
Journal:  Pharmacogenetics       Date:  1995-02

6.  Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.

Authors:  L J Notarianni; S E Oliver; P Dobrocky; P N Bennett; B W Silverman
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

7.  Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.

Authors:  B K Tang; Y Zhou; D Kadar; W Kalow
Journal:  Pharmacogenetics       Date:  1994-06

8.  Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins.

Authors:  I Chung; E Bresnick
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

Review 9.  Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity.

Authors:  D L Eaton; E P Gallagher; T K Bammler; K L Kunze
Journal:  Pharmacogenetics       Date:  1995-10

10.  CYP1A2 activity as a risk factor for bladder cancer.

Authors:  S W Lee; I J Jang; S G Shin; K H Lee; D S Yim; S W Kim; S J Oh; S H Lee
Journal:  J Korean Med Sci       Date:  1994-12       Impact factor: 2.153

View more
  28 in total

Review 1.  Pharmacogenetics of asthma.

Authors:  A Fenech; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women.

Authors:  Anna Nordmark; Stefan Lundgren; Birgitta Ask; Fredrik Granath; Anders Rane
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Gender-Related Differences in the Expression of Organic Cation Transporter 2 and its Role in Urinary Excretion of Metformin in Rats.

Authors:  Yan-Rong Ma; Hong-Yan Qin; Yong-Wen Jin; Jing Huang; Miao Han; Xing-Dong Wang; Guo-Qiang Zhang; Yan Zhou; Zhi Rao; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

4.  Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Authors:  Junling Yang; Minxia M He; Wei Niu; Steven A Wrighton; Li Li; Yang Liu; Chuan Li
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

5.  In vitro Phase I- and Phase II-Drug Metabolism in The Liver of Juvenile and Adult Göttingen Minipigs.

Authors:  Els Van Peer; Frank Jacobs; Jan Snoeys; Jos Van Houdt; Ils Pijpers; Christophe Casteleyn; Chris Van Ginneken; Steven Van Cruchten
Journal:  Pharm Res       Date:  2017-01-17       Impact factor: 4.200

6.  Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism".

Authors:  Jose Rodríguez-Morató; Albert Goday; Klaus Langohr; Clara Pérez-Mañá; Magí Farré; Rafael de la Torre
Journal:  Obes Surg       Date:  2017-11       Impact factor: 4.129

Review 7.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers.

Authors:  T Simon; L Becquemont; B Hamon; E Nouyrigat; Y Chodjania; J M Poirier; C Funck-Brentano; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

9.  Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.

Authors:  Xing-Mei Han; Dong-Sheng Ouyang; Xiao-Ping Chen; Yan Shu; Chang-Hong Jiang; Zhi-Rong Tan; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

10.  Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects.

Authors:  Naoto Uemura; Tatsuo Onishi; Akira Mitaniyama; Takeshi Kaneko; Kohji Ninomiya; Koichi Nakamura; Masao Tateno
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.